Published in Drug Week, September 5th, 2003
In a recent study in Africa, the safety and the efficacy of three potential CQ replacement regimens - AQ alone, "AQ plus sulfadoxine-pyrimethamine (SP) (AQ plus SP), and artesunate (ART) plus SP (ART plus SP)" - were evaluated "in 379 Rwandan children 6-59 months old with uncomplicated Plasmodium falciparum malaria who visited one urban/peri-urban health center and two rural health centers."
"The three treatment regimens were well-tolerated and no serious adverse effects were observed," noted C.E. Rwagacondo and coauthors working with Rwanda's National...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.